Corvus Pharmaceuticals, Inc. CRVS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +30.26%
- 1 year
- +29.25%
- Open
- 10.09
- Prev close
- 10.23
- Mkt cap
- 843.73M
- Vol
- 845.13K
- Avg vol
- 1.00M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.78
- High
- 10.37
- Forward P/E
- -11.75
- Beta
- 0.86
- Short ratio
- 25.31
- Inst. own
- 85.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 13.94
- 200-d avg
- 14.03
- 1y target
- 33.14
5D chart
Signals (89)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 10:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:25 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:05 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 4:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| RSI: Oversold | Oct 26, 2:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
3 days ago globenewswire.com
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a…
2 weeks ago benzinga.com
Corvus Pharma Q2 2026 Earnings Call Transcript
Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought…
1 month ago defenseworld.net
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price gapped up before the market opened on Tuesday. The stock had previously closed at $11.87, but opened at $12.37. Corvus…
-
1 month ago benzinga.com
Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of…
1 month ago globenewswire.com
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in…
1 month ago globenewswire.com
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership…
2 months ago globenewswire.com
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated…
2 months ago seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected…
-
2 months ago benzinga.com
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of…
2 months ago globenewswire.com
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis and…
3 months ago globenewswire.com
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
3 months ago defenseworld.net
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 5.1% – Should You Buy?
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) were up 5.1% during mid-day trading on Friday. The company traded as high as $14.91 and last traded at $14.9910. 120,438 shares…
4 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
4 months ago fool.com
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business.
-
4 months ago benzinga.com
Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel…
4 months ago globenewswire.com
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a…
4 months ago seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership…
5 months ago seekingalpha.com
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early
Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following encouraging but limited Phase 1 AD data. Soquelitinib shows activity in atopic dermatitis, but…
5 months ago fool.com
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
5 months ago seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
5 months ago globenewswire.com
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential…
5 months ago globenewswire.com
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting…
6 months ago benzinga.com
Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings
Stocks traded higher with Dow Jones up by 1,000 points. Consumer discretionary shares rose while energy stocks fell. State Street Corp reported upbeat earnings.
6 months ago benzinga.com
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday
The Dow Jones index rose 700 points, Autoliv Inc (NYSE: ALV) reported strong results causing a jump in its shares by 8.4% to $120.77. Other big gainers included CRML, ABTC, MFI, BYND, RXT, SHMD,…
6 months ago benzinga.com
This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
7 months ago benzinga.com
Earnings Scheduled For March 12, 2026
Earnings Scheduled For March 12, 2026
9 months ago benzinga.com
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session
9 months ago benzinga.com
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 months ago benzinga.com
Crude Oil Gains 2%; D.R. Horton Earnings Top Views
Crude Oil Gains 2%; D.R. Horton Earnings Top Views
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 months ago benzinga.com
Corvus Pharmaceuticals, Immunitybio, Acadia Healthcare And Other Big Stocks Moving Higher On Tuesday
Corvus Pharmaceuticals, Immunitybio, Acadia Healthcare And Other Big Stocks Moving Higher On Tuesday
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago benzinga.com
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
-
1 year ago benzinga.com
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Earnings Scheduled For November 12, 2024
Earnings Scheduled For November 12, 2024
-
2 years ago benzinga.com
Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are…